Selenium and Prostate Cancer; Clinical Trial on Availability to Prostate Tissue and Effects on Gene Expression.

• Conditions: prostate cancer; prostatic neoplasms; 10038597; 10036958

• Registration Number: NL-OMON30578
• Lead Sponsor: Wageningen Universiteit

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

Male
Caucasian ethnicity
Biopsy-proven prostate cancer
Scheduled for radical prostatectomy

Exclusion Criteria

Adjuvant therapy for prostate cancer (e.g. HIFU, hormonal therapy)
Use of dietary supplements
Previously or concurrent diagnosed with cancer (other than prostate cancer)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Levels of selenium in prostate tissue and changes in prostate gene expression<br /><br>profiles of participants supplemented with selenium or placebo, compared before<br /><br>and after the short intervention period, will be considered as the main<br /><br>parameters of the present study. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Besides gene expression profiles in prostate tissue, also gene expression<br /><br>profiles of peripheral mononuclear cells, levels of selenium in blood and<br /><br>toenails and blood flow and permeability of blood vessels of prostate tissue<br /><br>will be analyzed to examine the biological effects of selenium supplementation. </p><br>